Study Title: Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Children and Adults (OUtMATCH)

Study Objectives & Details: Our researchers are trying to determine if a study medication called omalizumab alone or combined with oral immunotherapy may help people with multiple food allergies. Participants must have a peanut allergy and at least two other food allergies to milk, egg, wheat, cashew, hazelnut, or walnut.

Enrollment: This trial is active and currently enrolling.

How to Participate: For more information, call 919-962-4406 or email OUtMATCH@unc.edu.

Who Can Participate: Anyone between the ages of 2-55 years who has a peanut allergy and at least two other food allergies to milk, egg, wheat, cashew, hazelnut or walnut.

Age Range: 2-55 years

Gender: Any

Desired Keywords: Food allergy, peanut allergy, oral immunotherapy

Estimated Time Commitment (# of visits, etc.): This is a multi-stage study, with an individual study participation of up to 4 years and 8 months, but not past December 2023.

Study Location: University of North Carolina at Chapel Hill

Compensation: Provided

Study Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Site Principal Investigator: Edwin Kim, MD

Study Coordinator: Lauren Herlihy, CPNP

Study Primary Investigator: Robert Wood, MD